

Please complete the ABSTRACT TEMPLATE online, for Biomed 2023 Company Presentations

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

All items marked with an * are mandatory to complete

The maximum number of words for this abstract is 400

Please be sure to complete the following:

Company name: Quris-AI * Website: <https://www.quris.ai/> *

CEO name: Dr. Isaac Bentwich *

Select a CATEGORY: Biotech/Pharma *

(Delete categories you are not selecting)

Select up to two SESSIONS per abstract from the list below *

(Delete sessions you are not selecting)

5. AI tapestry: optimizing the interaction of AI and Biopharma

You may delete the section instructions, leaving **only the bolded bullet title**

Answers below should not exceed 60 words per question:

- **Executive Summary / Investment Rational**
Quris-AI is developing a Bio-AI Clinical Prediction platform to reliably predict clinical safety of drug candidates. Quris is led by a stellar team of pharma and tech visionaries and has recently raised \$37M Seed from SoftBank and others. The company has strong IP on its novel technology, and collaborations with leading pharma to evaluate safety of pre-clinical and clinical assets.
- **Core Technology**
Drug safety is a serious issue, with 92% of drugs failing clinical trials despite passing animal testing, resulting in a \$53B loss for pharma companies annually. Quris' Bio-AI platform combines patient-on-chip data, real-time sensing, stem-cell genomic diversity, and advanced machine learning to enhance the prediction of drug candidate safety, reducing the high costs of failed clinical trials and animal testing. **Product**
- **Profile/Pipeline**
Quris-AI uses patient-on-chip data, real-time sensing, and machine learning to predict drug safety for pharma companies. The platform includes stem-cell genomic diversity and multiple organ models to develop personalized medicines for diverse populations. Quris-AI is partnering with top pharma firms, and planning to expand its pipeline with more genetic backgrounds and organ models.
- **Business Strategy**
Quris-AI uniquely combines cutting-edge AI together with hundreds of genomically diversified patients-on-chip to better predict drug safety. Quris works exclusively with top pharmaceutical firms to apply its patented techniques to advance their drug discovery and development initiatives. Revenue is derived from fixed fees for predictions, increasing annual exclusivity fees as phases progress, and success fees for phase approvals.

- **What's Next?**

Quris plans to finalize two new partnerships with leading pharma companies by year-end and add more organ models to its platform over the next two years, incorporating hundreds of genetically diverse patients-on-chip. The company opened a UAE subsidiary to develop personalized medicines for the MENA region's diverse populations. Quris aims to raise up to \$100M in its A-round.